When was Forendo Pharma founded?

Forendo Pharma was founded in 2013 and raised its 1st funding round within a year of its incorporation.

Where is Forendo Pharma located?

Forendo Pharma is headquartered in Turku, Finland.

Who is the current CEO of Forendo Pharma?

Risto Lammintausta of Forendo Pharma.

How many employees does Forendo Pharma have?

As of Jul 01, 2024, the latest employee count at Forendo Pharma is 19.

Is Forendo Pharma a funded company?

Forendo Pharma is a funded company, having raised a total of $25.6M across 5 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jun 25, 2013.

When was the latest funding round of Forendo Pharma?

Forendo Pharma's latest funding was a $***** Series A round on Jul 17, 2019, with participation from 6 investors.

Where does Forendo Pharma rank among its competitors?

Forendo Pharma ranks 7th amongst 31 active competitors, of which 10 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Gameto, which secured $44M in Jul, 2025.

Who are the top competitors of Forendo Pharma?

Forendo Pharma's top competitors include Gameto, Sprout Pharmaceuticals and Rejoni. Among them, Gameto secured the most recent funding round in July, 2025.

Forendo Pharma - 2026 Company Profile, Team, Funding & Competitors

Q: Is Forendo Pharma an acquired company?

Forendo Pharma got acquired by Organon on Nov 11, 2021.

Forendo Pharma is an acquired company based in Turku (Finland), founded in 2013 by Risto Lammintausta. It operates as a Provider of small molecule based therapeutics for reproductive health. Forendo Pharma has raised $25.6M in funding from investors like Sunstone, Finnvera and Karolinska Development. The company has 31 active competitors, including 10 funded and 6 that have exited. Its top competitors include companies like Gameto, Sprout Pharmaceuticals and Rejoni.

Company Details

Forendo Pharma develops small molecule therapeutics for reproductive health. The company specializes in tissue-specific regulation of sex hormone effects and has two candidates in the pipeline. The flagship product of the company Fispemifene is a selective estrogen receptor modulator (SERM) that is expected to treat male hypogonadism and is currently in phase II of the clinical trial. The other candidate is an inhibitor of the HSD17B1 enzyme and is under investigation for the treatment for endometriosis.

Website: forendo.com
Social

Key Metrics

Founded Year

2013

Location

Turku, Finland

Stage

Acquired

Total Funding

$25.6M in 5 rounds

Latest Funding Round

Series A, Jul 17, 2019, $*****

Investors

Sunstone & 9 more

Ranked

7^th among 31 active competitors

Employee Count

19 as on Jul 01, 2024

Similar Companies

Gameto & 30 more

Exit Details

Acquired by Organon (Nov 11, 2021)

View Forendo Pharma's full profile

Forendo Pharma got acquired by Organon on Nov 11, 2021 at an acquisition amount of $75M. It was facilitated by Moelis & Company.

Click here to take a look at Forendo Pharma's acquisition in detail

Forendo Pharma has raised a total funding of $25.6M over 5 rounds. Its first funding round was on Jun 25, 2013. Its latest funding round was a Series A round on Jul 17, 2019 for $*****. 6 investors participated in its latest round. Forendo Pharma has 10 institutional investors.

Here is the list of recent funding rounds of Forendo Pharma:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 17, 2019	2314737	Series A	4434338	4256773	6703543	2885784
Sep 05, 2018	8346781	Series A	2726821	5824872	7339411	3558632
Mar 19, 2018	4943936	Conventional Debt	8824876	2204353	1829814	Businessfinland

Access funding benchmarks and valuations. Sign up today!

View details of Forendo Pharma's funding rounds and investors

The founders of Forendo Pharma is Risto Lammintausta.

Here are the details of Forendo Pharma's key team members:

Risto Lammintausta: Co-Founder & CEO of Forendo Pharma and founder of 1 other company.

View details of Forendo Pharma's Founder profiles and Board Members

Forendo Pharma's employee count trend

Forendo Pharma has 19 employees as of Jul 24. Here is Forendo Pharma's employee count trend over the years:

Uncover Forendo Pharma's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Forendo Pharma include Gameto, Sprout Pharmaceuticals and Rejoni. Here is the list of Top 10 competitors of Forendo Pharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Gameto 2020, United States, Series C	Developer of therapeutics for the treatment of fertility and menopause	$127M	RA Capital Management, Insight Partners & 29 others	58/100
2nd	Sprout Pharmaceuticals 2011, Raleigh (United States), Acquired	Developer of drugs for hypoactive sexual desire disorder in women	$185M	New Ventures Funds, Lunsford Capital & 1 others	58/100
3rd	Rejoni 2020, Bedford (United States), Series B	Developer of therapeutics to treat women health conditions	$41.3M	Ascension Ventures, CHV & 6 others	57/100
4th	Hope Medicine 2018, Shanghai (China), Series B	Developer of monoclonal antibodies for the treatment of multiple diseases	$56M	Sinovation Ventures, Qiming Venture Partners ... & 7 others	54/100
5th	Naari 2007, Noida (India), Acquired	Manufacturer of women care medicines	$19M	Ascent Capital, Jagsonpal & 17 others	51/100
6th	ObsEva 2012, Geneva (Switzerland), Public	Developer of therapeutics for women's reproductive health and pregnancy	$94.7M	Sofinnova Partners, New Enterprise Associates ... & 17 others	47/100
7th	Forendo Pharma 2013, Turku (Finland), Acquired	Provider of small molecule based therapeutics for reproductive health	$25.6M	M Ventures, Novartis Venture Fund & 8 others	46/100
8th	PregLem 2006, Geneva (Switzerland), Acquired	Drugs for women's reproductive medicine	$57.9M	Sofinnova Investments, MVM & 2 others	45/100
9th	FimmCyte 2022, Basel (Switzerland), Funding Raised	Developer of therapeutics to treat endometriosis	-	Venture Kick, BaseLaunch & 2 others	44/100
10th	Nora Therapeutics 2007, Palo Alto (United States), Series B	Developer of therapeutics to address IVF failure and recurrent pregnancy loss	$37.8M	Novo Holdings, Vivo Capital & 3 others	43/100